In particular, they are characterized by a relatively low miR-204 expression with respect to non-MYCN amplified neuroblastoma cell lines (30), an ideal condition to investigate the effects of this microRNA not only in tumors of the sympathetic nervous system but also in neurodevelopmental conditions. This evidence concerns the gene MYCN and neuroblastoma.